The Biotech Startups Podcast
🧬 Choosing the Right VC: What Money Can’t Buy | Jacob Glanville Re-Release (Part 4/4)
December 25, 2025
"If you can synthesize, then there's no such thing as too much expertise." We’re revisiting some of our previous episodes over the holidays this year. Our next re-release is this episode of The Biotech Startups Podcast, where Jacob Glanville pulls back the curtain on the “black box” of venture capital for biotech founders, sharing what he learned moving from pitching antibody platforms to pitching VCs. He explains how aligning with each firm’s investment thesis, simplifying your story, and using sharp visuals—while treating fundraising like dating, not a numbers game—can dramatically improve your odds without ever resorting to exaggeration or dishonesty.​ Jacob then dives into choosing the right venture partners, negotiating fair terms, and focusing on what real success looks like for both founders and investors. He shows how the best VCs act as strategic allies and “polishing engines,” and explains why he partnered with NFX and GHIC to help drive Centivax’s universal vaccine programs forward, from RNA-LNP–enabled flu vaccines to broad-spectrum efforts in HIV and coronaviruses, all powered by a village of mentors, collaborators, and family.​
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science.

As a TBSP listener, you can get exclusive perks through Excedr’s partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners.

"If you can synthesize, then there's no such thing as too much expertise."

We’re revisiting some of our previous episodes over the holidays this year. Our next re-release is this episode of The Biotech Startups Podcast, where Jacob Glanville pulls back the curtain on the “black box” of venture capital for biotech founders, sharing what he learned moving from pitching antibody platforms to pitching VCs. He explains how aligning with each firm’s investment thesis, simplifying your story, and using sharp visuals—while treating fundraising like dating, not a numbers game—can dramatically improve your odds without ever resorting to exaggeration or dishonesty.​

Jacob then dives into choosing the right venture partners, negotiating fair terms, and focusing on what real success looks like for both founders and investors. He shows how the best VCs act as strategic allies and “polishing engines,” and explains why he partnered with NFX and GHIC to help drive Centivax’s universal vaccine programs forward, from RNA-LNP–enabled flu vaccines to broad-spectrum efforts in HIV and coronaviruses, all powered by a village of mentors, collaborators, and family.​

Key topics covered:

If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening.​

Subscribe to the Podcast:
Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994
Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4
Youtube: https://www.youtube.com/@thebiotechstartupspodcast 
Website: https://www.thebiotechstartupspodcast.com/ 

Find our guest, Jacob Glanville, at these links: 
LinkedIn: https://www.linkedin.com/in/jacobglanville/
Website: https://www.centivax.com/
 
Find our host, Jon Chee, at these links: 
LinkedIn: https://www.linkedin.com/in/jonchee

Learn more about Excedr:
LinkedIn: https://www.linkedin.com/company/excedr/ 
Website: https://www.excedr.com

Intro & Outro Songs Created by OkKyojin, Owned by Excedr:
Website: https://flow.page/kyojin 

Resources & Articles:
Building Backwards to Biotech (Book by Stephanie Wisner): https://books.google.com/books/about/Building_Backwards_to_Biotech.html?id=6pwlzwEACAAJ
Venture Capital Investment Thesis Explained: https://www.investopedia.com/terms/i/investment-thesis.asp
RNA-LNP (Lipid Nanoparticle) Vaccine Technology: https://en.wikipedia.org/wiki/Lipid-based_nanoparticle
IND-Enabling Studies for Clinical Trials: https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
HAI Titer and Vaccine Efficacy Correlates: https://pmc.ncbi.nlm.nih.gov/articles/PMC6530189/
Good Manufacturing Practice (GMP) Standards: https://safetyculture.com/topics/gmp
Negotiation Strategies for Founders: https://hbr.org/2014/04/15-rules-for-negotiating-a-job-offer
Series A Fundraising for Biotech Startups: https://www.excedr.com/resources/what-it-takes-to-raise-a-series-a
Contract Research Organizations (CROs) in Drug Development: https://novotech-cro.com/blog/what-role-cros-drug-development

Companies, Universities, & People mentioned:
NFX https://www.nfx.com​​
Global Health Investment Corporation (GHIC) https://ghicfunds.org​​
Twist Bioscience https://www.twistbioscience.com
Charles River Laboratories https://www.criver.com/ 
Endpoints News https://endpts.com/
Stephanie Wisner https://www.linkedin.com/in/stephanie-wisner-5aa4556a/

Timestamps: 
00:00 Intro
01:00 Condensing the Pitch Deck and Lessons from Fundraising
01:26 Finding Mentors and Understanding VC Culture
07:45 Handling Rejection and Learning from Feedback
11:42 Choosing the Right VC: Beyond Just the Money
16:54 Negotiation Strategy and Fair Terms
19:01 Building Awareness and Living Rent-Free in People's Minds
20:11 Centivax's Next Steps: Universal Vaccines and RNA LNP Technology
24:58 Phase 1 Clinical Trials and Platform Validation
25:49 Shout-Outs to Team Members and Collaborators
29:15 Outro

The Biotech Startups Podcast gives you a front-row seat to the business and science of building a biotech. Hosted by Jon Chee, CEO of Excedr, the show features honest conversations with founders, execs, and investors about their work, their companies, and how they got there. From scientific breakthroughs to startup lessons, each episode explores what it really takes to grow a life science company—from pre-seed to IPO.